FrancophonIA/ELRC3.0 huggingface dataset:
English: Subjects of D-Pan-H5N1-010 were followed up for persistence of the immune response.
Estonian: D-Pan-H5N1-010 uuringu uuritavaid jälgiti immuunvastuse püsimise suhtes edasi.
English: Prepandrix suspension and emulsion for emulsion for injection Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Estonian: Prepandrix, suspensioon ja emulsioon süsteemulsiooni valmistamiseks Prepandeemiline gripiviiruse vaktsiin (H5N1) (inaktiveeritud purustatud viirus, adjuveeritud)
English: Ferrets were vaccinated on days 0 and 21 and challenged by the intra-tracheal route on day 49 with a lethal dose of either H5N1/A/Vietnam/1194/04 or heterologous H5N1/A/Indonesia/5/05.
Estonian: Päeval 49 manustati neile trahheasse surmav annus H5N1/A/Vietnam/1194/04 või heteroloogset H5N1/A/Indonesia/5/05 viirust.
English: PHARMACEUTICAL FORM AND CONTENTS Suspension and emulsion for emulsion for injection 50 vials: suspension (antigen)
Estonian: Suspensioon ja emulsioon süsteemulsiooni valmistamiseks 50 suspensiooni (antigeeni) viaali
English: The anti-HA and neutralising antibody responses to A/Indonesia/05/2005 elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from this same strain have been shown to be comparable with the immune responses to A/Vietnam/1194/2004 elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from this same strain.
Estonian: AS03-adjuveeritud, 3,75 µg A/Indonesia/05/2005-st tuletatud HA sisaldusega vaktsiini poolt esile kutsutud anti-HA ja neutraliseerivate antikehade vastus sellele samale tüvele on osutunud võrreldavaks AS03-adjuveeritud, 3,75 µg A/Vietnam/1194/2004-st tuletatud HA sisaldusega vaktsiini poolt esile kutsutud anti-HA ja neutraliseerivate antikehade vastusega sellele samale tüvele.
English: How to store Prepandrix
Estonian: Kuidas Prepandrixi säilitada
English: From post-marketing experience with AS03-containing vaccines containing 3.75 µg HA derived from A/California/7/2009 (H1N1), the following adverse reactions have been reported:
Estonian: 3,75 μg A/California/7/2009 (H1N1) tüvest saadud HA-d sisaldavad AS03 adjuvandiga vaktsiinide turule tuleku järgses perioodis on teatatud järgmistest kõrvalnähtudest.
English: Skin and subcutaneous tissue disorders Common: ecchymosis at the injection site, sweating increased Uncommon: pruritus, rash
Estonian: Naha ja nahaaluskoe kahjustused Sage: süstekoha hematoom, suurenenud higistamine Aeg-ajalt: sügelus, lööve
English: • if you have previously had a sudden life-threatening allergic reaction to any ingredient of this vaccine (listed in section 6) or to anything else that may be present in very small amounts such as: egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate (antibiotic) or sodium deoxycholate.
Estonian: • kui olete selle ravimi mis tahes koostisosa(de) (loetletud lõigus 6) või ükskõik missuguse muu aine suhtes, mida vaktsiinis võib esineda väga väikeses koguses, näiteks: muna- ja kanavalk, ovalbumiin, formaldehüüd, gentamütsiinsulfaat (antibiootikum) või naatriumdeoksükolaat suhtes allergiline.
English: Subjects of D-Pan-H5N1-002 were followed up for persistence of the immune response.
Estonian: D-Pan-H5N1-002 uuringu uuritavaid jälgiti immuunvastuse püsimise suhtes ka edaspidi.
English: Very rare: may affect up to 1 in 10,000 people
Estonian: Väga harva: võivad esineda vähem kui ühel inimesel 10 000-st
English: Subjects of D-Pan-H5N1-009 were followed up for persistence of the immune response.
Estonian: D-Pan-H5N1-009 uuringu uuritavaid jälgiti immuunvastuse püsivuse suhtes ka edaspidi.
English: METHOD OF ADMINISTRATION Mix with adjuvant emulsion before use
Estonian: MANUSTAMISVIIS Enne manustamist segada adjuvandi emulsiooniga.
English: Month 24
Estonian: 24 kuu pärast
English: One dose of 0.5 ml at an elected date.
Estonian: Täiskasvanud vanuses alates 18 aasta vanusest: üks 0,5 ml annus valitud kuupäeval.
English: The seroprotection rates 6, 12, 24 and 36 months after the first dose were as follows: anti-HA antibody
Estonian: Seroprotektsiooni määrad 6, 12, 24 ja 36 kuud pärast esimest annust olid järgmised.
English: Geometric Mean Titre
Estonian: 1 geomeetriline keskmine tiiter
English: Seroprotection rate
Estonian: Seroprotektsiooni määr1
English: STATEMENT OF ACTIVE SUBSTANCE(S) Split influenza virus, inactivated, containing antigen* equivalent to 3.75 micrograms haemagglutinin/dose *Antigen: A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)
Estonian: Inaktiveeritud purustatud gripiviirus, mille antigeeni* sisaldus on ekvivalentne: 3,75 mikrogrammi hemaglutiniini/annuses *Antigeen: A/Indonesia/05/2005 (H5N1) sarnane tüvi (PR8-IBCDC-RG2)
English: Tell the doctor requesting these tests that you have recently received Prepandrix.
Estonian: Teavitage analüüse läbiviivat arsti Prepandrixi hiljutisest manustamisest.
English: NAME OF THE MEDICINAL PRODUCT Suspension for emulsion for injection for Prepandrix Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Estonian: Suspensioon Prepandrixi süsteemulsiooni valmistamiseks Prepandeemiline gripiviiruse vaktsiin (H5N1) (inaktiveeritud purustatud viirus, adjuveeritud)
English: Therefore, the data that have been generated with AS03adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 are considered to be relevant to the use of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005.
Estonian: Seega loetakse AS03-adjuveeritud, 3,75 µg A/Vietnam/1194/2004-st tuletatud HA sisaldusega vaktsiini kasutamisega saadud andmeid paikapidavaks ka AS03-adjuveeritud, 3,75 µg A/Indonesia/5/2005-st tuletatud HA sisaldusega vaktsiini puhul.
English: Split influenza virus, inactivated, containing antigen equivalent to: A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)
Estonian: Inaktiveeritud purustatud gripiviirus, mille antigeeni sisaldus on ekvivalentne: A/Indonesia/05/2005 (H5N1) sarnane tüvi (PR8-IBCDC-RG2)
English: Special population:
Estonian: Eripopulatsioon
English: One dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 administered after one or two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004.
Estonian: Üks AS03-adjuveeritud, 3,75 µg A/Indonesia/05/2005-st tuletatud HA sisaldusega vaktsiini annus manustatuna pärast ühte või kahte AS03-adjuveeritud, 3,75 µg A/Vietnam/1194/2004-st tuletatud HA sisaldusega vaktsiini annust
English: Immune response against A/Indonesia/05/2005 (H5N1) In a clinical study (Q-Pan-H5N1-001) in which two doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005 were administered on days 0 and 21 to 140 subjects aged 18-60 years, the anti-HA antibody responses were as follows: anti-HA antibody
Estonian: Kliinilises uuringus (Q-Pan-H5N1-001), milles kaks AS03-adjuveeritud, 3,75 µg A/Indonesia/05/2005-st tuletatud HA sisaldusega vaktsiini annust manustati päevadel 0 ja 21 isikutele vanuses 18…60 aastat, olid antikeha vastused järgmised: anti-HA antikeha
English: METHOD OF ADMINISTRATION Mix into Antigen suspension before use
Estonian: MANUSTAMISVIIS Enne manustamist segada antigeeni suspensiooniga.
English: GlaxoSmithKline Biologicals Branch of SmithKline Beecham Pharma GmbH & Co. KG Zirkusstraße 40, D-01069 Dresden Germany
Estonian: KG Zirkusstraße 40, D-01069 Dresden Saksamaa
English: In the subjects aged 3 to 5 and 6 to 9 years old who received two doses of either a full or a half dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1), the anti-HA antibody responses against A/Indonesia/5/2005 at day 42 were as follows:
Estonian: 3…5-aastastel ja 6…9-aastastel lastel, kellele manustati kas kaks täisannust (0,5 ml) või kaks poolannust (0,25 ml) AS03 adjuvandiga vaktsiini, mis sisaldas 3,75 µg A/Vietnam/1194/2004 (H5N1) tüvest tuletatud HA-d, olid anti-HA antikehade vastused A/Indonesia/5/2005 tüve vastu päeval 42 järgmised.
English: One pack containing: - one pack of 50 vials (type I glass) of 2.5 ml suspension with a stopper (butyl rubber).
Estonian: Pakend: - ühes pakendis 50 korgiga (butüülkumm) viaali (I tüüpi klaas) 2,5 ml suspensiooniga - kahes pakendis 25 korgiga (butüülkumm) viaali (I tüüpi klaas) 2,5 ml emulsiooniga
English: 2 4-fold increase in serum neutralising antibody titre 3 % of subjects reaching a serum neutralising antibody titre of at least 1:80
Estonian: 2 Seerumi neutraliseerivate antikehade tiitri 4-kordne suurenemine 3 Uuritavate %, kellel seerumi neutraliseerivate antikehade tiiter oli vähemalt 1:80
English: • Increased sweating, shivering, flu-like symptoms
Estonian: • Suurenenud higistamine, külmavärinad, gripitaolised nähud
English: Induration
Estonian: Imetamine
English: An extended dosing interval was investigated in study D-H5N1-012 in which a group of subjects 1860 years of age received two doses of Prepandrix containing the A/Vietnam/1194/2004 strain 6 months or 12 months apart.
Estonian: Uuringus D-H5N1-012 uuriti pikemat annustevahelist intervalli ning selle käigus manustati 18...60aastastele isikutele kaks Adjupanrixi annust 6- või 12-kuulise vahega.
English: Talk to your doctor or nurse before you are given Prepandrix:
Estonian: Enne Prepandrixi manustamist pidage nõu oma arsti või meditsiiniõega, kui:
English: In a clinical study (D-Pan-H5N1-012), subjects aged 18-60 years received a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from either A/Vietnam/1194/2004 or Indonesia/5/2005 six months after they had received one or two priming doses of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 on day 0 or on days 0 and 21.
Estonian: Kliinilises uuringus (D-Pan-H5N1-012) said isikud vanuses 18…60 aastat annuse AS03-adjuveeritud, 3,75 µg kas A/Vietnam/1194/2004-st või A/Indonesia/05/2005-st tuletatud HA sisaldusega vaktsiini kuus kuud pärast seda kui nad olid saanud üks või kaks AS03-adjuveeritud, 3,75 µg A/Vietnam/1194/2004-st tuletatud HA sisaldusega vaktsiini esmast annust vastavalt päeval 0 või päevadel 0 ja 21.
English: A clinical study (D-H5N1-009) evaluated the reactogenicity in children 3 to 5 and 6 to 9 years of age who received either two adult (i.e. 0.5 ml) doses or two half adult (i.e. 0.25 ml) doses (21 days apart) of pandemic preparedness vaccine (H5N1 A/Vietnam/1194/2004 manufactured in Dresden, Germany).
Estonian: Kliinilises uuringus (D-H5N1-009) hinnati teise pandeemilise valmisoleku vaktsiini (H5N1 A/Vietnam/1194/2004, toodetud Saksamaal Dresdenis) reaktogeensust 3- kuni 5-aastastel ja 6- kuni 9aastastel lastel, kellele manustati (21-päevase vahega) kas kaks täiskasvanu annust (st 0,5 ml) või kaks täiskasvanu poolannust (st 0,25 ml).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Content: AS03 adjuvant composed of squalene (10.69 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)
Estonian: Koostis: adjuvant AS03, mis sisaldab skvaleeni (10,69 milligrammi), DL-α-tokoferooli (11,86 milligrammi) ja polüsorbaat 80 (4,86 milligrammi)
English: • if you have had any allergic reaction other than a sudden life threatening allergic reaction to any ingredient contained in this vaccine (listed in section 6) or to thiomersal, to egg and chicken protein, ovalbumin formaldehyde, gentamicin sulphate (antibiotic) or to sodium deoxycholate.
Estonian: • teil on tekkinud allergiline reaktsioon vaktsiini mõne koostisosa (loetletud lõigus 6) või tiomersaali, muna- ja kanavalgu, ovalbumiini, formaldehüüdi, gentamütsiinsulfaadi (antibiootikum) või naatriumdeoksükolaadi suhtes;
English: In a clinical study (D-Pan-H5N1-009), children aged 3 to 5 and 6 to 9 years old received two doses of either a full (0.5 ml) or a half dose (0.25 ml) of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) at 0 and 21 days.
Estonian: Ühes kliinilises uuringus (D-Pan-H5N1-009) manustati 3…5aastastele ja 6…9aastastele lastele kas kaks täisannust (0,5 ml) või kaks poolannust (0,25 ml) A/Vietnam/1194/2004 (H5N1) tüvest tuletatud 3,75 µg HA-d sisaldava AS03-adjuvandiga vaktsiini päevadel 0 ja 21.
English: Month N=47
Estonian: Täisannus N = 47
English: • Other ingredients:
Estonian: • Abiained on:
English: Cross-reactive immune responses elicited by AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1):
Estonian: A/Vietnam/1194/2004 (H5N1) tüvest tuletatud 3,75 µg HA-d sisaldava AS03-adjuvandiga vaktsiini poolt esile kutsutud rist-reaktiivsed immuunvastused
English: Administration of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1)
Estonian: A/Vietnam/1194/2004 (H5N1) tüvest tuletatud 3,75 µg HA-d sisaldava AS03-adjuvandiga vaktsiini manustamine
English: It is essentially sodium- and potassium-free.
Estonian: Ravim on praktiliselt naatriumi- ja kaaliumivaba.
English: 2booster seroconversion rate: proportion of subjects who were either seronegative at pre-booster and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-booster and have a 4fold increase in titre;
Estonian: korduse serokonversiooni määr: isikute hulk, kes enne kordusvaktsineerimist olid seronegatiivsed ning kellel pärast vaktsineerimist oli kaitsvate antikehade tiiter ≥ 1:40, või kes enne kordusvaktsineerimist olid seropositiivsed ning kellel esines 4-kordne antikehade tiitri tõus;
English: There are very limited safety and immunogenicity data available on the administration of an AS03adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) and on administration of half a dose of the vaccine (i.e. 1.875 µg HA and half the amount of AS03 adjuvant) at 0 and 21 days in children aged 3 to 9 years.
Estonian: A/Vietnam/1194/2004 (H5N1) tüvest tuletatud 3,75 µg HA-d sisaldava AS03-adjuvandiga vaktsiini ja vaktsiini poole annuse (st 875 μg HA ja poole koguse AS03 adjuvandi) manustamise kohta 3- kuni 9
English: In clinical studies that evaluated the immunogenicity of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) in subjects 18-60 years old, the anti-haemagglutinin (anti-HA) antibody responses were as follows:
Estonian: µg HA-d tuletatud tüvest A/Vietnam/1194/2004, isikutel vanuses 18-60 aastat, olid anti-hemaglutiniini (anti-HA) antikehade vastused järgmised:
English: • if you have problems with your immune system, since your response to the vaccine may then be poor.
Estonian: Teie organismi vastus vaktsiinile võib sellisel juhul jääda ebapiisavaks.
English: Immune response to A/Indonesia/5/2005
Estonian: A/Indonesia/5/2005 immuunvastus
English: This leaflet was last revised in
Estonian: Infoleht on viimati uuendatud KK.AAAA Muud teabeallikad
English: Pain
Estonian: ABIAINED
English: • Swollen glands in your neck, armpit or groin
Estonian: • Kaela, kaenlaaluste või kubeme lümfisõlmede suurenemine
English: The vaccine should be administered in accordance with the recommended posology (see section 4.2).
Estonian: Vaktsiin tuleb manustada vastavalt soovitatud annustamisskeemile.
English: It should be given at the same time each day.
Estonian: Seda tuleb manustada iga päev samal ajal.
English: Ganfort bimatoprost / timolol
Estonian: Ganfort bimatoprost/timolool
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ganfort on 19 May 2006.
Estonian: Euroopa Komisjon andis Ganforti müügiloa, mis kehtib kogu Euroopa Liidus, 19. mail 2006.
English: What measures are being taken to ensure the safe and effective use of Ganfort?
Estonian: Mis meetmed võetakse, et tagada Ganforti ohutu ja efektiivne kasutamine?
English: The full EPAR for Ganfort can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ganforti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Other information about Ganfort
Estonian: Muu teave Ganforti kohta
English: The values were lowered by about 8-10 mmHg.
Estonian: Silma siserõhk vähenes ligikaudu 8-10 mmHg võrra.
English: Ganfort is given as one drop in the affected eye(s) once a day, either in the morning or the evening.
Estonian: Ganforti manustatakse ühe tilgana haige(te)sse silma(desse) üks kord ööpäevas kas hommikuti või õhtuti.
English: Ganfort is an eye drops solution that contains two active substances: bimatoprost (0.3 mg/ml) and timolol (5 mg/ml).
Estonian: Ganfort on silmatilkade lahus, mis sisaldab kaht toimeainet: bimatoprosti (0,3 mg/ml) ja timolooli (5 mg/ml).
English: Ganfort must not be used in patients who have asthma or severe lung disease, or in patients with some heart conditions.
Estonian: Ganforti ei tohi kasutada patsiendid, kellel on astma, raske kopsuhaigus või teatud südamehaigused.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ganfort have been included in the summary of product characteristics and the package leaflet.
Estonian: Ganforti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The CHMP decided that Ganfort's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Ganforti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: If more than one type of eye drop is being used, each one should be given at least five minutes apart.
Estonian: Mitut liiki silmatilkade kasutamisel tuleb jätta nende manustamise vahele vähemalt 5 minutit.
English: For more information about treatment with Ganfort, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ganfortiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Ganfort.
Estonian: See on ravimi Ganfort Euroopa avaliku hindamisaruande kokkuvõte.
English: It is used in adults with ‘open angle glaucoma' or ocular hypertension who do not respond sufficiently to eye drops containing beta-blockers or prostaglandin analogues (other medicines used for these conditions).
Estonian: Seda kasutatakse avatud nurga glaukoomiga või okulaarse hüpertensiooniga täiskasvanutel, kellel ei saavutata piisavalt head tulemust beetablokaatoreid või prostaglandiini analooge sisaldavate silmatilkadega (nende haigusseisundite ravimiseks kasutatavad teised ravimid).
English: The studies compared Ganfort with bimatoprost, timolol, or bimatoprost and timolol given at the same time after three weeks to four months of treatment.
Estonian: Uuringutes võrreldi Ganforti mõju bimatoprosti, timolooli või üheaegselt manustatud bimatoprosti ja timolooli mõjuga pärast 3 nädalat kuni 4 kuud kestnud ravi.
English: The main measures of effectiveness were the average reduction in eye pressure or the number of patients whose eye pressure fell below the target of 18 mmHg (making it within the normal range).
Estonian: Efektiivsuse põhinäitaja oli kas silmarõhu keskmine vähenemine või nende patsientide arv, kellel vähenes silmarõhk alla sihtväärtust 18 mmHg, jõudes normaalvahemikku.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ganfort.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effect (seen in more than 1 patient in 10) is conjunctival hyperaemia (increased blood supply to the eye, leading to redness of the eye).
Estonian: Kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on sidekesta hüpereemia (silma suurenenud verevarustus, mis põhjustab silmapunetust).
English: In addition, more patients given Ganfort had a drop in pressure of more than 20% (67.9% against 48.9%).
Estonian: Ganforti ravirühmas oli ka rohkem neid, kelle silmarõhk vähenes üle 20% võrra (67,9%, bimatoprosti uuringurühmas 48,9%).
English: By lowering the pressure, Ganfort reduces the risk of damage.
Estonian: Rõhku alandades vähendab Ganfort kahjustuse tekke riski.
English: Overall, the studies showed that Ganfort is effective in lowering eye pressure.
Estonian: Üldiselt tõendasid uuringud, et Ganfort on silma siserõhu alandamisel efektiivne.
English: In addition, Ganfort was shown to be as effective as bimatoprost and timolol given at the same time.
Estonian: Lisaks tõendati, et Ganfort on sama efektiivne kui üheaegselt manustatud bimatoprost ja timolool.
English: What is Ganfort?
Estonian: Mis on Ganfort?
English: Ganfort was more effective than timolol on its own and was as effective as bimatoprost.
Estonian: Ganfort oli efektiivsem kui üksnes timolool ja sama efektiivne kui üksnes bimatoprost.
English: What is the risk associated with Ganfort?
Estonian: Mis riskid Ganfortiga kaasnevad?
English: ‘Ocular hypertension' is when the pressure in the eye is higher than normal.
Estonian: Okulaarse hüpertensiooni korral on silmarõhk normaalsest suurem.
English: Ganfort is used to reduce the pressure inside the eye.
Estonian: Ganforti kasutatakse silma siserõhu vähendamiseks.
English: Ganfort contains two active substances, bimatoprost and timolol, which lower the pressure in the eye in different ways.
Estonian: Ganfort sisaldab kaht toimeainet, bimatoprosti ja timolooli, mis alandavad silma siserõhku erimoodi.
English: Raised pressure in the eye causes damage to the retina (the light sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Estonian: Silma siserõhu suurenemine kahjustab võrkkesta (silma tagaosas asuv valgustundlik pind) ja silmanärvi, mille kaudu liiguvad närvisignaalid silmast ajju.
English: Why has Ganfort been approved?
Estonian: Miks Ganfort heaks kiideti?
English: For the full list of all side effects reported with Ganfort, see the package leaflet.
Estonian: Ganforti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Ganfort lowered the pressure to less than 18 mmHg in 18.7% of these patients compared with 10.2% with bimatoprost only.
Estonian: Patsiente, kelle silma siserõhk vähenes alla vääruse 18 mmHg, oli Ganforti uuringurühmas 18,7% ja ainult bimatoprosti rühmas 10,2%.
English: Four main studies have been performed involving 1,964 adults with ocular hypertension or glaucoma.
Estonian: Ganforti uuriti neljas põhiuuringus, milles osales 1964 okulaarse hüpertensiooni või glaukoomiga täiskasvanud patsienti.
English: Timolol is a beta-blocker that works by reducing the production of fluid within the eye. Timolol has been commonly used to treat glaucoma since the 1970s.
Estonian: Timolooli on glaukoomi raviks laialdaselt kasutatud juba 1970. aastatest.
English: Bimatoprost is a prostaglandin analogue, (a copy of the natural substance prostaglandin) that works by increasing the drainage of fluid out of the eye. Bimatoprost on its own has already been approved in the European Union under the name Lumigan.
Estonian: Bimatoprost on prostaglandiini analoog (loodusliku aine prostaglandiini sünteetiline variant), mis suurendab vedeliku väljavoolu silmast.
English: How is Ganfort used?
Estonian: Kuidas Ganforti kasutatakse?
English: Ganfort was, however, more effective than bimatoprost in patients whose pressure was not controlled with eye drops containing prostaglandins alone.
Estonian: Patsientidel, kelle silmarõhku ei saanud reguleerida üksnes prostaglandiini sisaldavate silmatilkadega, oli Ganfort efektiivsem kui bimatoprost.
English: What benefit has Ganfort shown during the studies?
Estonian: Milles seisnes uuringute põhjal Ganforti kasulikkus?
English: What is Ganfort used for?
Estonian: Milleks Ganforti kasutatakse?
English: How has Ganfort been studied?
Estonian: Kuidas Ganforti uuriti?
English: How does Ganfort work?
Estonian: Kuidas Ganfort toimib?